The global Pneumonia Testing Market size was valued at $1.6 billion in 2020, and is projected to reach $3.0 billion by 2030, growing at a CAGR of 6.5% from 2021 to 2030. Pneumonia is a complicated infection that affects the lower respiratory tract and is characterized by symptoms, such as short breathing, fever, chest pain, nausea, and vomiting. Air sacs of the lungs called as alveoli are filled with fluid or pus that cause inflammation during pneumonia. It is mainly caused by microorganisms, such as bacteria, virus, fungi, and parasites, which affects people with weakened immune systems and is common in children and the geriatric population. The treatment of pneumonia depends on the severity of symptoms and types of pathogens. Antibiotics are given to treat pneumonia caused by bacterial infections. Antifungals are prescribed to treat pneumonia caused by fungi. It is quite difficult to diagnose pneumonia as its clinical symptoms overlap with many other diseases, such as asthma, bronchitis, and the common cold.
The key factor that drives the Pneumonia Testing Market Growth is a rise in the adoption of point of care(POC) testing and development in the field of nucleic acid detection across the world. In addition, increase in the geriatric population, the surge in advances in pneumonia diagnostics, and growth in prevalence of pneumonia among children across the globe fuel the growth of the market. Furthermore, increase in healthcare expenditure, presence of advanced healthcare infrastructure, availability of reimbursements, and the presence of key market players are Pneumonia Testing Market Opportunity, However, the traditional method, cultures are still mostly used to detect pneumonia causative organisms which can hamper the market growth to a certain extent during the forecast period as this traditional method is a time-consuming process with a higher error rate.
The Pneumonia Testing Industryis segmented on the basis of method, technology, type & end user . Depending on the method, it is classified into immunodiagnostics, molecular diagnostics, and point-of-care (POC) testing. By type, it is bifurcated into analyzers and consumables. Based on technology, it is categorized into enzyme-linked immunosorbent assay (ELISA), immunofluorescence, western blot, polymerase chain reaction (PCR), immunohistochemistry (IHC), and others. As per end users, it is segregated into hospitals, diagnostic laboratories, home care, and others. Region-wise the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By Method Segment Review
Depending on the method, the point-of-care (POC) testing segment holds the largest market and is expected to witness the highest CAGR during the forecast period. prevalence of pneumonia across the world, due to various reasons, such as an increase in the geriatric population, sedentary lifestyles, unhealthy food habits, and environmental factors.
By Type Segment Review
By type, the analyzers segment holds the largest market share in 2020 and is expected to remain dominant in thePneumonia Testing Market Forecast, owing to their frequent usage for pneumonia tests are the key factors anticipating the growth of the market.
By Technology Segment Review
As per technology, the enzyme-linked immunosorbent assay segment holds the largest market share in 2020 and is expected to remain dominant during the forecast period. An increase in demand for advanced diagnostic techniques and a rise in a number of contract research organizations (CROs) are the key factors anticipating the growth of the market in the future.
By End-user Segment Review
By end-user, the hospital segment is the major contributor to the market growth, owing to the increase in the number of patients suffering from pneumonia and the rise in the demand for diagnostic tests across the globe.
Region segment Review
Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America has the highest Pneumonia Testing Market Share in 2020, owing to a rise in prevalence of chronic diseases, growth in healthcare expenditure, the surge in presence of advanced healthcare infrastructure, increase in the availability of reimbursements, and rise in presence of major market players in the region are the major factors driving the growth of the pneumonia testing market in North America.
The key players operating in the Pneumonia Testing Industry include Thermo Fisher Scientific Inc., Abbott Laboratories, F-Hoffmann la Roche Ltd., Hologic Inc., BioMerieux, Becton, Dickenson and Company, Bio-Rad Laboratories Inc., Meridian Biosciences, Quest Diagnostics, and Quidel.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pneumonia testing market analysis from 2020 to 2030 to identify the prevailing pneumonia testing market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the pneumonia testing market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global pneumonia testing market trends, key players, market segments, application areas, and market growth strategies.
Pneumonia Testing Market, by Types Report Highlights
| Aspects | Details |
 By Type |
|
 By Method |
|
 By Technology |
|
 By End User |
|
 By Region |
|
 Key Market Players | Hologic Inc, F.hoffman La roche, Thermofischer Inc, Beckton and Dickinson Company, Biomerieux SA, Bio Rad laborateries, Quidel Corporation, AdvanDx, Beckman Coulter, Abott Laboratories |
Analyst Review
According to the CXOs of the leading companies, the demand for pneumonia testing is increasing rapidly, owing to the surge in the incidence of pneumonia, which, in turn, propels the growth of the pneumonia therapeutics market during the forecast period. Furthermore, rise in the prevalence of community-acquired pneumonia, especially in younger individuals is expected to fuel the growth of the market in the future.
In addition, an increase in the prevalence of infection in the respiratory tract demonstrates unmet clinical needs, which propels the demand for pneumonia therapeutics in the future. In addition, the surge in R&D related to the treatment methods drives the market growth. However, the traditional method and cultures are used to detect pneumonia causative organisms which can hamper the market growth to a certain extent during the forecast period, as this traditional method is a time-consuming process with a higher error rate.
On the contrary, the surge in investments in the development of newer products, such as pneumonia testing kits is anticipated to create remunerative growth opportunities for the expansion of the pneumonia testing market during the forecast period.
The total market value of the Pneumonia Testing Market is $1,586.9o million in 2030
$2,975.35 million is the estimated industry size of Pneumonia Testing in 2030
The upcoming trends in the Pneumonia Testing Market are an increase in awareness regarding early diagnosis, a rise in popularity of point of care (POC)testing, and a surge in government expenditures on healthcare
North America is the largest regional market for Pneumonia Testing?
Thermo Fisher Scientific Inc., Abbott Laboratories, F-Hoffmann la Roche Ltd., Hologic Inc., bioMerieux, Becton, Dickenson, and Company are the top companies to hold the market share in Pneumonia Testing
Loading Table Of Content...
